Anavex Life Sciences (AVXL) Change in Receivables (2015 - 2019)
Anavex Life Sciences (AVXL) reported Change in Receivables of $17154.0 for Q2 2019, up 1412.7% on a YoY basis from $1134.0 in Q2 2018, and down 62.54% sequentially from $45788.0 in Q1 2019.
Anavex Life Sciences (AVXL) Change in Receivables (2015 - 2019) Analysis & Trends
Anavex Life Sciences (AVXL) has 5 years of Change in Receivables data on file, last reported at $17154.0 in Q2 2019.
- For the quarter ending Q2 2019, Change in Receivables rose 1412.7% year-over-year to $17154.0; the trailing twelve-month figure through Jun 2019 stood at $87169.0 (up 4309.03% YoY), and the FY2018 full-year result was $30423.0, up 155.89% from the prior year.
- Change in Receivables eased to $17154.0 in Q2 2019, from $45788.0 in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $45788.0 in Q1 2019 to a low of -$37256.0 in Q2 2017.
- A 5-year average of $2109.2 and a median of $1134.0 in 2018 frame the typical range for Change in Receivables.
- Peak annual rise in Change in Receivables reached 2121.02% in 2018, while the deepest fall reached 313.29% in 2018.
- Tracing AVXL's Change in Receivables over 5 years: stood at $15497.0 in 2015, then slumped by 294.99% to -$30217.0 in 2016, then jumped by 92.15% to -$2371.0 in 2017, then tumbled by 313.29% to -$9799.0 in 2018, then jumped by 275.06% to $17154.0 in 2019.
- Business Quant data shows AVXL's Change in Receivables at $17154.0 in Q2 2019, $45788.0 in Q1 2019, and -$9799.0 in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 75.30 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 2.84 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -39.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -1.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Anavex Life Sciences | 229.83 Mn | 98.08 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2019 | 17,154.00 |
| Jun 30, 2019 | 17,154.00 |
| Mar 31, 2019 | 45,788.00 |
| Mar 31, 2019 | 45,788.00 |
| Dec 31, 2018 | -9,799.00 |
| Dec 31, 2018 | -9,799.00 |
| Sep 30, 2018 | 34,026.00 |
| Sep 30, 2018 | 34,026.00 |
| Jun 30, 2018 | 1,134.00 |
| Jun 30, 2018 | 1,134.00 |
| Mar 31, 2018 | -2,366.00 |
| Mar 31, 2018 | -2,366.00 |
| Dec 31, 2017 | -2,371.00 |
| Dec 31, 2017 | -2,371.00 |
| Sep 30, 2017 | 1,532.00 |
| Sep 30, 2017 | 1,532.00 |
| Jun 30, 2017 | -37,256.00 |
| Jun 30, 2017 | -37,256.00 |
| Mar 31, 2017 | 11,506.00 |
| Mar 31, 2017 | 11,506.00 |